Turning a blind eye:Why we don't test for blindness at the end of our trials
Year: 2004
Type: letter
Abstract: EDITOR—I write with reference to the paper by Fergusson et al.1 Asking patients or their clinicians at the end of a trial which drug they think they were taking confounds failures in blinding with successes in pre-trial hunches about efficacy.
Thirty years ago, at the end of the first ever trial of aspirin and sulfinpyrazone …
Source: BMJ
Author: David L Sackett
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W2023797366
